• Corpus ID: 147486009

Purine Nucleoside Mediated Neuroprotection in the 6-Hydroxydopamine Rodent Model of Parkinson's Disease

@inproceedings{Terpstra2011PurineNM,
  title={Purine Nucleoside Mediated Neuroprotection in the 6-Hydroxydopamine Rodent Model of Parkinson's Disease},
  author={Brian T. Terpstra},
  year={2011}
}
Purine Nucleoside Mediated Neuroprotection in the 6-Hydroxydopamine Rodent Model of Parkinson’s Disease Brian T. Terpstra, Doctor of Philosophy, 2010 Dissertation directed by: Timothy J. Collier, Ph.D. Professor of Translational Science and Molecular Medicine ______________________________ Signature Parkinson’s Disease (PD) is a progressive, neurodegenerative disorder characterized by bradykinesia, akinesia, and resting tremor. While dopamine replacement therapy effectively eliminates symptoms… 

Award Number: W81XWH-11-1-0150 TITLE: Protection by Purines in Toxin Models of Parkinson's Disease PRINCIPAL INVESTIGATOR:

Results implicate GSH as the extracellular astrocytic factor mediating the protective effect of urate in a cellular model of PD and show that urate can employ a novel indirect neuroprotective mechanism via induction of the Nrf2 signaling pathway, a master regulator of the response to oxidative stress, inAstrocytes.

Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration

A neuroprotective role of endogenous urate in dopaminergic neurons is supported and the rationale for developing urate-elevating strategies as potential disease-modifying therapy for Parkinson’s disease is strengthened.

References

SHOWING 1-10 OF 45 REFERENCES

Etiology and Pathogenesis of Parkinson’s Disease

Genetic factors clearly contribute to the pathogenesis of Parkinson’s disease, and many studies have shed light on their implication in, not only monogenic, but also sporadic forms of PD.

Reassessment of Caspase Inhibition to Augment Grafted Dopamine Neuron Survival

Examining the efficacy of two different caspase inhibitors to augment mesencephalic tyrosine hydroxylase-immunoreactive (TH-ir) neuron survival in culture and following implantation into the denervated striatum of rats concluded that treatment with Ac-YVAD-CMK provided partial but nonsignificant protection for TH-ir neurons against serum withdrawal.

Dopamine cell replacement: Parkinson's disease.

Basic scientific knowledge of neural transplants is incomplete and warrants a prudent approach toward application of neural transplantation techniques in clinical research.

Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

After improvement in the first year, dystonia and dyskinesias recurred in 15 percent of the patients who received transplants, even after reduction or discontinuation of the dose of levodopa.

Interference with anoikis‐induced cell death of dopamine neurons: Implications for augmenting embryonic graft survival in a rat model of Parkinson's disease

Pretreatment with tenascin may prove beneficial to prevent anoikis‐induced cell death in dilute cell suspension grafts, while long‐term in vivo delivery methods need to be explored to determine if L1 can prevent anOikis in grafts of mesencephalic dopamine neurons after transplantation.

BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons

It is suggested that application of this factor might similarly improve the clinical efficacy of neural transplantation employed in the treatment for Parkinson's disease by exerting a significant effect on the functional reinnervation of the striatum by transplanted fetal dopamine neurons in the rat.

Changes in somatodendritic but not terminal dopamine
regulation in aged rhesus monkeys

In comparison to the massive loss of DA neurons responsible for the movement dysfunctions seen in Parkinson's disease, pronounced functional changes in DA release in the SN and putamen may significantly contribute to the motoric Dysfunctions characterizing normal aging in rhesus monkeys.